Ratings MedinCell LIQUIDNET SYSTEMS

Equities

FR0004065605

Real-time Estimate Tradegate Other stock markets 11:12:05 2024-06-07 EDT			5-day change	1st Jan Change
15.12 ^EUR	0.00%		0.00%	0.00%

05-15	Medincell: share price falls after disappointing clinical study	CF
05-15	Transcript : MedinCell S.A. - Special Call

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For the past twelve months, EPS forecast has been revised upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
Based on current prices, the company has particularly high valuation levels.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
MEDINCELL	0.00%	481M	-
ELI LILLY AND COMPANY	+45.78%	754B	C+
NOVO NORDISK A/S	+40.85%	630B	B
JOHNSON & JOHNSON	-5.56%	352B	C+
MERCK & CO., INC.	+20.20%	331B	B-
ABBVIE INC.	+9.70%	298B	C+
ASTRAZENECA PLC	+18.72%	250B	B+
NOVARTIS AG	+12.10%	217B	B-
ROCHE HOLDING AG	-0.61%	216B	A+
AMGEN INC.	+6.56%	164B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes